Evaluation of cardiac magnetic resonance imaging in detection of cardiotoxicity in patients with lymphoma treated with anthracyclines

Isabela Bispio Santos da Silva Costa1, Bruno Morhy Borges Leal Assunção1, Cecília Beatriz Bittencourt Viana Cruz1, André Vinche Badra Pavan1, Juliana Pereira1, Valéria Bucherin2, Marcelo Bellosta2, Cristiana Salvadori Bitte2, Stephanie Itala Riki1, Diego Ribeiro Garcia1, Altamir Féras Osório1, julia Tizue Fukushima1, Antonio Fernando Lins de Palva1, Marcos Garcia1, Carlos Eduardo Negri2, Roberto Ralli Filho3, César Higa Nomura4, Carlos Eduardo Rochitte5, Ludmila Alfredo Hajjar6.

1Cancer Institute of São Paulo, University of São Paulo 2Heart Institute of São Paulo, University of São Paulo

BACKGROUND

- Lymphoma treated with anthracyclines have survival rates of 86% at 5 years. However, cardiac toxicity of these drugs usually leads to advanced heart failure.
- Current strategies for early detection of cardiotoxicity during chemotherapy are not yet fully established.

METHODS

A pilot study, with a sample of 48 patients. Prospective observational study.
- Local: Cancer Institute of São Paulo, University of São Paulo
- Period: From June 2017 to March 2019.

Inclusion criteria:
- Age ≥ 18 years-old
- Confirmed diagnosis of lymphoma
- Candidates for chemotherapy with anthracyclines
- Signed the informed consent.

Exclusion criteria:
- Previous cardiomyopathy
- Uncontrolled hypertension
- HIV positive
- Renal failure (Cr>2.0mg/dl)
- Pregnancy
- Compromised performance status (ECOG> 3 or KPS <60).
- Contraindications to CMR.

RESULTS

- Cardiotoxicity was defined as drop of the left ventricular fractional (LVEF) > 10% or LVEF decrease below 50%.

CONCLUSIONS

- Others clinical outcomes: Thrombocytopenia: 8 (16.0%) patients
- Death: 2 (8.0%) patients

REFERENCES


DISCLOSURES

All the authors have no conflicts of interest to disclose.

This presentation is the intellectual property of the author. Contact: isabela.bispio@iic.ufmg.br for permission to reprint and/or distribute.